2023 COMPLEMENT UK TRAINING COURSE AND SYMPOSIUM

COMPLEMENT DIAGNOSTICS AND THERAPEUTICS

3-4 APRIL 2023

CARDIFF UNIVERSITY

POSTER PRESENTATIONS

P-01 Lack of Complement Factor H contributes to endothelial cell injury in Shiga toxin Haemolytic Uraemic Syndrome, Emily Bowen

P-02 Functional relevance of genetic associations at complement genes with risk of Alzheimer's disease, Samuel Keat

P-03 Characterising complement in amyloid-beta plaques, Lewis Watkins

P-04 GWAS of plasma complement protein levels reveals functional effects of Alzheimer's disease risk loci, Aurora Veteleanu

P-05 Evaluation of minimal Factor H therapy administered to kidneys during ex vivo normothermic perfusion as a treatment to improve ischaemia reperfusion injury, Chloe Connelly

P-06 Performance of a C2 Assay for use with EDTA plasma, Lithium Heparin plasma, and serum on the Binding Site Optilite Analyser, Jake Fisher

P-07 Performance of a C1q Assay for use with Serum, EDTA plasma and Lithium Heparin plasma on the Binding Site Optilite Analyser, Iasmina Gavrilas

P-08 The potent anti-inflammatory product of HMGB1 cleavage by the complement C1s, Marie Lorvellec

P-09 Generation of Novel Antibodies Targeting the Putative Complement Regulatory Domain of CSMD1, Robert Byrne

P-10 Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development, Martin Schmidt

P-11 Complement dysregulation in Long COVID, Kirstie Baillie

P-12 Roles of complement dysregulation and membrane attack complex formation in developmental synapse loss, Sarah Carpanini

P-13 Complement in clinical trials: the search for human complement challenge models, Juliette van den Noort

P-14 Complement receptor 1 is expressed on brain cells and impacts roles of microglia relevant to Alzheimer's disease, Nikoleta Daskoulidou

P-15 A Novel Functional Properdin Assay – Studying the Positive AP Regulator and Complement Amplification Loop, Samuel Butler

P-16 Differential expression of complement activation markers in the blood of individuals with clinical high-risk for pyschosis, Eleftheria Kodosaki

P-17 Utilising biomarkers to diagnose MS and predict long-term outcomes, Eleftheria Kodosaki

P-18 Measurement of complement deposition at the neuromuscular junction in passive transfer myasthenia gravis in rats, Anja Schöttler

P-19 Complement activation in response to hypoxia and reoxygenation in tubular epithelial cells, Saltanat Moldakhmetova

P-20 Differentiating between activation via the lectin or the classical complement pathway in Systemic Lupus Erythematosus patients, Mads Lamm Larsen

P-21 Safety, Tolerability and Pharmacodynamic Effects of ARO-C3, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting Complement C3, in Adult Healthy Volunteers, Hamid Moradi

P-22 Levels of soluble complement regulators predict severity of COVID-19 symptoms, Anna Tierney

P-23 Complement inhibitors for age-related macular degeneration (AMD): A Cochrane systematic review and meta-analysis, Nikolas Tzoumas

P-24 Complement profiles throughout adolescent development, Laura Westacott

P-25 PET/CT imaging of Blood-Brain Barrier Integrity and inflammatory tracers during Alzheimer's Disease, Basma Alenezi